Wuppertal, Germany

Stefan Weigand

USPTO Granted Patents = 17 


 

Average Co-Inventor Count = 8.5

ph-index = 9

Forward Citations = 457(Granted Patents)


Location History:

  • Wuppertal, DE (2004 - 2010)
  • Penzberg, DE (2007 - 2015)

Company Filing History:


Years Active: 2004-2015

Loading Chart...
Loading Chart...
Loading Chart...
17 patents (USPTO):

Title: The Innovative Contributions of Stefan Weigand

Introduction

Stefan Weigand is a notable inventor based in Wuppertal, Germany. He has made significant contributions to the field of medicinal chemistry, holding a total of 17 patents. His work primarily focuses on the development of novel compounds for the treatment and prevention of various diseases.

Latest Patents

Among his latest patents are "Bicyclic aza heterocycles, and use thereof" and "Pyrimidyl derivatives as protein kinase inhibitors." The first patent relates to novel bicyclic azaheterocycles, detailing processes for their preparation and their use in treating cardiovascular disorders. The second patent focuses on compounds that serve as protein kinase inhibitors, which are crucial in the control or prevention of illnesses such as cancer.

Career Highlights

Stefan Weigand has worked with prominent companies in the pharmaceutical industry, including Bayer Aktiengesellschaft and Bayer Healthcare Aktiengesellschaft. His experience in these organizations has allowed him to contribute to significant advancements in drug development.

Collaborations

Throughout his career, Weigand has collaborated with esteemed colleagues such as Johannes-Peter Stasch and Cristina Alonso-Alija. These partnerships have further enhanced his research and innovation efforts.

Conclusion

Stefan Weigand's contributions to medicinal chemistry and his innovative patents underscore his importance in the field. His work continues to impact the development of treatments for critical health issues.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…